# CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES

> **NIH NIH N01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $30,034

## Abstract

There is a demand for estrogen-free contraception in order to reduce the risk of venous 
thromboembolism (VTE), particularly for obese women. A new oral contraceptive agent 
consisting of a progesterone receptor modulator, which does not affect endogenous estrogen 
levels, has been developed. Ulipristal acetate (UPA) has been used in a single high dose for 
emergency contraception and has been used continuously for up to six months for treatment of 
uterine fibroids. Low dose continuous usage of oral UPA is anticipated to inhibit ovulation and 
provide an estrogen free, bleed free method of contraception.

## Key facts

- **NIH application ID:** 10329659
- **Project number:** 275201300002I-P00005-27500003-1
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** LIVIA WAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $30,034
- **Award type:** —
- **Project period:** 2014-09-19 → 2021-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10329659

## Citation

> US National Institutes of Health, RePORTER application 10329659, CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES (275201300002I-P00005-27500003-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10329659. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*